致：香港交易及結算所有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 呈交日期: 2025年10月8日 公司名稱: 中國匯融金融控股有限公司 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01290 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | 0 | | | | HKD | | 0 | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | ...

Core Viewpoint - Dongxing Medical plans to acquire 90% equity of Wuhan Yijiaobao, which is expected to constitute a major asset restructuring [2][10] Group 1: Acquisition Details - On September 26, Dongxing Medical signed a "Share Acquisition Intent Agreement" with all shareholders of Wuhan Yijiaobao to purchase 90% of its equity for cash [3][4] - The final transaction price will be based on an evaluation report from a qualified asset appraisal agency as per the Securities Law of the People's Republic of China [9] - A exclusivity period is set from the signing date until May 31, 2026, during which the current shareholders cannot negotiate with other parties regarding the equity transfer [9] Group 2: Strategic Rationale - The acquisition aligns with Dongxing Medical's business development strategy and aims to integrate high-quality industry resources, extending its surgical medical device supply chain and actively expanding into the synthetic biology field [11][13] - Wuhan Yijiaobao specializes in high-end orthopedic and biomedical materials, holding multiple medical device registration certificates [11][13] Group 3: Financial Performance - Dongxing Medical's main business has shown a declining trend since its listing on November 30, 2022, with net profits decreasing from 1.03 billion yuan in 2021 to an estimated 664.59 million yuan in 2024 [15] - In the first half of 2025, Dongxing Medical's revenue fell by 14.17% year-on-year to 183.29 million yuan, and net profit dropped by 36.47% to 30.29 million yuan [18][19]

Core Viewpoint - Dongxing Medical plans to acquire 90% equity of Wuhan Yijiaobao, which is expected to constitute a major asset restructuring [1][2]. Group 1: Acquisition Details - On September 26, Dongxing Medical signed a "Share Acquisition Intent Agreement" with all shareholders of Wuhan Yijiaobao to purchase 90% of its equity for cash [2]. - The final transaction price will be based on an evaluation report from a qualified asset appraisal agency as per the Securities Law of the People's Republic of China [7]. - A exclusivity period is established from the signing date until May 31, 2026, during which the sellers cannot negotiate with other parties regarding the equity transfer [7]. Group 2: Strategic Intent - The acquisition is part of Dongxing Medical's strategic need for business development and aims to extend its surgical medical device industry chain while actively expanding into the synthetic biology field [8]. - Wuhan Yijiaobao specializes in high-end orthopedic and biomedical materials, holding multiple medical device registration certificates [8][10]. Group 3: Financial Performance - Dongxing Medical's main business has shown a declining trend since its listing on the Shenzhen Stock Exchange on November 30, 2022, with net profits decreasing from 1.03 billion yuan in 2021 to an estimated 664.59 million yuan in 2024 [11]. - In the first half of 2025, Dongxing Medical's revenue fell by 14.17% to 183.29 million yuan, and net profit dropped by 36.47% to 30.29 million yuan [13][14].

基于公司业务发展战略的需要具体来看，东星医疗，90%的股权。若本次交易能顺利实施完成，公司将 持有武汉医佳宝90%的股权目前，此次。东星医疗已经与，但东星医疗表示，东星医疗2025年6月，公 司委托上海交通大学进行重组胶原蛋白的研发，拟拓展合成生物业务板块。武汉医佳宝是一家致力于高 端骨科及生物医学材料研发、生产与销售的高新技术企业。 拟收购武汉医佳宝9月26日，东星医疗（301290）公告，"武汉医佳宝"或"标的公司"）90%的股权 交易 如能顺利实施，武汉医佳宝将成为 的控股子公司。 武汉医佳宝东星医疗表示，此次。 的股权关系较为清晰，其只有两名股东，分别为持股9月26日，东星医疗股价收于27.96元/股，市值约 28亿元。截至今年9月，公司股东约1.04万户。 ...

CHINA HUIRONG FINANCIAL HOLDINGS LIMITED 中國匯融金融控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：1290） 各位非登記股東1 ： 於本公司網站登載公司通訊之通知 謹此通知 閣下，中國匯融金融控股有限公司（「本公司」）之下述公司通訊（「2 本次公司通訊」）之中、英文 版本，現已登載於本公司網站www.cnhuirong.com（「本公司網站」）及香港聯合交易所有限公司（「聯交所」） 網站www.hkexnews.hk（「聯交所網站」）以供閱覽： • 2025中期報告 請於本公司網站「投資者關係」一欄或聯交所網站內讀取本次公司通訊。若 閣下早前曾要求收取公司通 訊的印刷本，本次公司通訊的印刷本已隨函附上。 1. 非登記股東指將所持有之本公司股份存放於中央結算系統的人士或公司。 2. 公司通訊包括本公司發佈或將予發佈以供其任何證券持有人或投資大眾參照或採取行動的任何文件，其中包括 但不限於(a)董事會報告，公司年度帳目連同核數師報告以及（如適用）財務摘要報告；(b)中期報告及（如適用）中 期摘要報告；(c)季度報告（如有）；(d)會議通告；(e)上市文件；( ...

CHINA HUIRONG FINANCIAL HOLDINGS LIMITED 中國匯融金融控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：1290） 各位註冊股東： 於本公司網站登載公司通訊之通知 謹此通知 閣下，中國匯融金融控股有限公司（「本公司」）之下述公司通訊（「1 本次公司通訊」）之中、英文 版本，現已登載於本公司網站www.cnhuirong.com（「本公司網站」）及香港聯合交易所有限公司（「聯交所」） 網站www.hkexnews.hk（「聯交所網站」）以供閱覽： • 2025中期報告 請於本公司網站「投資者關係」一欄或聯交所網站內讀取本次公司通訊。若 閣下早前曾要求收取公司通 訊的印刷本，本次公司通訊的印刷本已隨函附上。 為了支援通過電郵進行電子通訊，本公司建議 閣下向本公司香港股份過戶登記分處卓佳證券登記有限 公司（「香港股份過戶登記分處」）（地址為香港夏慤道16號遠東金融中心17樓）發出（不少於7天的）合理書 面通知，或發送電郵至1290-ecom@vistra.com向本公司提供 閣下的電郵地址。 股東有責任提供有效的電郵地址。若 閣下沒有提供有效的電郵地址，本公司將透過 ...

2025 中期報告 INTERIM REPORT 2025 CHINA HUIRONG FINANCIAL HOLDINGS LIMITED 中國匯融金融控股有限公司 INTERIM REPORT 2025 中期報告 我們立志成為中國領先的綜合性 金融服務供應商。 我們正努力為我們的客戶提供典當、科技小貸、 商業保理、融資租賃、藝術品投資、股權投資、 特殊資產投資、轉貸基金等多種金融服務。 我們的業務主要覆蓋蘇州、青島、南京、 成都、武漢、合肥、長沙、南昌、 福州及香港，並不斷朝着中國領先的 普惠金融和生態金融服務供應商的 地位邁進。 目 錄 | 公司資料 | 2 | | --- | --- | | 財務摘要 | 4 | | 管理層討論與分析 | 5 | | 其他資料 | 45 | | 中期財務資料的審閱報告 | 52 | | 中期簡明合併綜合收益表 | 53 | | 中期簡明合併財務狀況表 | 55 | | 中期簡明合併權益變動表 | 57 | | 中期簡明合併現金流量表 | 58 | | 中期簡明合併財務信息附註 | 59 | | 釋義 | 107 | 中國匯融金融控股有限公司 1 二零二五年中期報告 公 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國匯融金融控股有限公司 呈交日期: 2025年9月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01290 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 HKD | | 100,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 HKD | | 100,000,000 | 本月底法定/註冊股本總額： HKD ...

Core Viewpoint - China Huirong (01290) reported a decrease in operating revenue for the six months ending June 30, 2025, primarily due to external factors affecting the macroeconomic environment and the real estate sector [1] Financial Performance - The company achieved operating revenue of 346 million yuan, representing a year-on-year decrease of 2% [1] - Profit attributable to equity holders amounted to 32.76 million yuan, reflecting a year-on-year increase of 7% [1] - Basic earnings per share were reported at 0.03 yuan [1] Factors Influencing Performance - The decline in operating revenue was mainly attributed to the contraction in debt-related business, particularly real estate mortgage loans, which led to a decrease in interest income [1] - The increase in profit attributable to equity holders was due to a reduction in the proportion of non-controlling interests, despite the overall profit decline [1]

Core Viewpoint - China Huirong (01290) reported a decrease in operating revenue for the six months ending June 30, 2025, primarily due to external factors affecting the macroeconomic environment and the real estate sector [1] Financial Performance - The company achieved operating revenue of 346 million yuan, representing a year-on-year decrease of 2% [1] - Profit attributable to equity holders amounted to 32.76 million yuan, reflecting a year-on-year increase of 7% [1] - Basic earnings per share were reported at 0.03 yuan [1] Reasons for Revenue Change - The decline in operating revenue was mainly attributed to the contraction of debt-related business, particularly real estate mortgage loans, which led to a decrease in interest income [1] - The increase in profit attributable to equity holders was due to a reduction in the proportion of non-controlling interests, despite the overall profit decline [1]